An FDA rebuke of televised comments made by Aegerion’s CEO—which led the company to air a TV commercial correcting the statements—was prompted by complaints from a government drug reviewer, according to emails viewed by The Wall Street Journal.
WSJ.com: Health, Wall Street Journal: Business: Health
Sun, 12/21/2014 - 6:06pm
An FDA rebuke of televised comments made by Aegerion’s CEO—which led the company to air a TV commercial correcting the statements—was prompted by complaints from a government drug reviewer, according to emails viewed by The Wall Street Journal.